Experienced Leader Brings Over 25 Years of Pharmaceutical and Medical Device Expertise to Vactech
Tampere, Finland, October 19, 2023 — Vactech Ltd., a leading biotechnology company specializing in vaccine development and medical innovation, is pleased to announce the appointment of Dr. Tero Välimaa as its new Chief Executive Officer, effective immediately.
Dr. Välimaa is a highly accomplished professional with a distinguished career spanning over 25 years in the pharmaceutical, surgical, and medical device sectors. He is renowned for his strategic leadership, research & development and project management expertise, and commitment to innovation. He has successfully guided numerous products from early development stages through to commercialization, securing funding and ensuring regulatory compliance along the way.
Prior founding ValoXion Consultancy, Dr. Välimaa held senior leadership positions at Santen Pharmaceutical Co., Ltd., a global leader in ophthalmology. Serving as Director of Global Alliances & Collaborations, he excelled in building and managing strategic partnerships that fostered innovation and growth. His role as Director of Global Research & Development Strategy saw him shaping the company's R&D direction in neuroprotection, glaucoma, and drug discovery, including work on orphan drugs, biologics, drug delivery systems, and medical devices.
"I am honored to join Vactech and lead the company into its next chapter of innovation and growth," said Dr. Välimaa. "Vactech has a strong legacy in vaccine development and a commitment to improving global health. I look forward to working with the talented team here to advance our mission and bring groundbreaking solutions to market."
The appointment of Dr. Välimaa comes at a pivotal time for Vactech as it continues to expand its research and development initiatives. His extensive experience in managing the full lifecycle of over 40 global products and his expertise in materials science, R&D regulatory compliance, and cross-functional team leadership are expected to significantly contribute to Vactech's strategic objectives.
"Dr. Välimaa's exceptional track record and visionary leadership make him the ideal choice to steer Vactech forward," said Professor Heikki Hyöty, Chairman of the Board at Vactech. "We are confident that his expertise will drive innovation and enhance our position as a leader in the biotechnology industry. We are also extremely thankful for the former CEO, Raimo Harju, whose 20-years long work was essential for the success of our clinical development programs”.
Vactech Ltd. is a biotechnology company based in Tampere, Finland, dedicated to the research and development of vaccines and medical innovations. With a focus on combating Type 1 Diabetes, Celiac Disease, and infectious diseases, Vactech leverages advanced technologies and strategic collaborations to improve global health and bring effective solutions to the market. The company's mission is to drive health technology advancements with precision, integrity, and expertise.
Media Contact:
Vactech Oy
Phone: +358 3 447 8111
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Website: www.vactech.fi